Moderna, Pfizer begin late-stage trials of Covid-19 vaccine candidates
Both vaccine candidates leverage advanced mRNA technologies for rapid development and manufacturing than traditional production methods
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Jul 20
Both vaccine candidates leverage advanced mRNA technologies for rapid development and manufacturing than traditional production methods
27 Jul 20
The additional BARDA funding will support the expanded Phase 3 study of Moderna’s potential Covid-19 vaccine candidate mRNA-1273
24 Jul 20
Jakavi demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy
21 Jul 20
AZD1222 was co-developed by the University of Oxford and its spin-out company, Vaccitech, and was licensed by AstraZeneca…
20 Jul 20
The Covid-19 vaccine candidate has been developed under the collaboration between Abu Dhabi-based G42 Healthcare and Sinopharm CNBG
14 Jul 20
Phase 3 IMagyn050 trial did not meet the primary endpoint of progression-free survival (PFS) for the treatment of…
13 Jul 20
The data includes a comparative analysis of clinical recovery and mortality outcomes from Phase 3 SIMPLE Trial versus…
06 Jul 20
Cabotegravir plus rilpivirine is an investigational regimen indicted for the treatment of HIV-1 infection in patients who are…
01 Jul 20
INO-4800 is a DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes Covid-19
22 Jun 20
Clover will begin phase 1 study of GSK’s Covid-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant…